Eloralintide
ELO / LY-3841136 · Amylin receptor agonist (investigational)
What it is
Eli Lilly's selective amylin agonist for weight management — the same hormone axis as cagrilintide and petrelintide. Now in Phase 3 (ENLIGHTEN program) after Phase 2 results in 2025; the "ELO" shorthand circulates outside the trials.
What human evidence shows
Phase 2 data reported meaningful weight loss with reported tolerability advantages, which is why it advanced to Phase 3 — but published safety and efficacy evidence remains incomplete while those trials run.
Risks
Using a drug mid-trial means the safety database is literally still being collected: the known amylin-class pattern (nausea, GI effects) plus whatever Phase 3 exists to find. Any purported product outside a registered study cannot be assumed to contain the investigational drug.
Legal status
US: investigational — unapproved, legitimately available only inside Lilly's trials.
Evidence base
early literature
Real human evidence: randomised trial reports, or review-level evidence backed by at least one human trial report.
- phase 3/4
- 0
- randomised
- 3
- reviews
- 1
- human trials
- 3
Counts are of published papers, not distinct trials, and measure how much research exists — not whether this works or is safe for you.
Research (7)
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of conceptMol Metab · 2025
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trialLancet · 2025
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of conceptDiabetes Obes Metab · 2026
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetesPeptides · 2026
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversiesMetabol Open · 2026
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical TrialsDiabetes Obes Metab · 2026
- Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-AnalysisEndocrinol Diabetes Metab · 2026
Turn Eloralintide into a plan that's yours
The info above is free. Membership makes it personal, the Coach answers questions about your exact stack, the Stack tracks it for you, and the Verified Sources shows you how to vet what you buy.
- ✓ AI Coach, ask anything about your stack. It does the dosing math, flags interactions, and tells you what to do next.
- ✓ Personal Stack, save your protocol, track it across devices, log doses, get a heads-up before a vial runs out.
- ✓ Verified Sources, the vetted reference for checking quality and sourcing, members only.
Cancel anytime · or save with $59.99/yr · Coach + Stack included